Australian Pharmaceutical Benefits Scheme to reimburse for Trelegy Ellipta

GSK Australia has announced that the Australian Pharmaceutical Benefits Scheme (PBS) will reimburse for Trelegy Ellipta for the treatment of moderate to severe COPD as of June 1, 2018.

According to a document on the Therapeutic Goods Administration (TGA) website, Trelegy Ellipta was entered into the Australian Register of Therapeutic Goods as of January 16, 2018.

GSK Australia Pharmaceutical Medical Director Andrew Weekes commented, “While people are struggling with breathlessness and having their lives negatively impacted by COPD, GSK will continue to research and develop new treatment options. GSK is committed to bringing our innovative medicines to the people that need them most and today’s announcement provides evidence of that.”

Read the GSK Australia press release.